Efficacy and tolerability of rizatriptan in pediatric migraineurs: Results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design

Cephalalgia

Volumn 32, Issue 10, 2012, Pages 750-765

  Ho, Tony W ^a   Pearlman, Eric ^b   Lewis, Donald ^c   Hämäläinen, Mirja ^d   Connor, Kathryn ^a   Michelson, David ^a   Zhang, Ying ^a   Assaid, Christopher ^a   Mozley, Lyn Harper ^a   Strickler, Nancy ^a   Bachman, Robert ^a   Mahoney, Erin ^a   Lines, Christopher ^a   Hewitt, David J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Savannah Neurology and Memorial University Medical Center   (United States)

^c Children's Hospital of the King's Daughters   (United States)

^d UNIVERSITY OF HELSINKI AND HELSINKI UNIVERSITY HOSPITAL   (Finland)

Author keywords

children; clinical trial; migraine; pediatric; Rizatriptan; triptans

Indexed keywords

ACETYLSALICYLIC ACID; BARBITURIC ACID DERIVATIVE; ERGOT DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; PLACEBO; RIZATRIPTAN;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADOLESCENT; ARTICLE; ASTHENIA; CHILD; CHILDHOOD DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; NAUSEA; PAIN ASSESSMENT; PARESTHESIA; PHARYNGITIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SOMNOLENCE; TREATMENT OUTCOME; VOMITING; XEROSTOMIA;

ADOLESCENT; CHILD; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIGRAINE DISORDERS; SEROTONIN RECEPTOR AGONISTS; TREATMENT OUTCOME; TRIAZOLES; TRYPTAMINES;

EID: 84864238949     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102412451358     Document Type: Article

References (20)

1. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart . Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007 ; 68: 343-349
2. Abu-Arafeh I, Razak S, Sivaraman B, Graham C. Prevalence of headache and migraine in children and adolescents: a systematic review of population-based studies. Dev Med Child Neurol. 2010 ; 52: 1088-1097
3. Hämäläinen ML, Hoppu K, Valkeila E, Santavuori P. Ibuprofen or acetaminophen for the acute treatment of migraine in children: a double-blind, randomized, placebo-controlled, crossover study. Neurology. 1997 ; 48: 103-107
4. Lewis DW, Kellstein D, Dahl G, et al. Children's ibuprofen suspension for the acute treatment of pediatric migraine. Headache. 2002 ; 42: 780-786
5. Lewis D, Ashwal S, Hershey A, et al. Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. Neurology. 2004 ; 63: 2215-2224
6. Lewis DW, Winner P, Wasiewski W. The placebo responder rate in children and adolescents. Headache. 2005 ; 45: 232-239
7. Winner P, Rothner AD, Wooten JD, Webster C, Ames M. Sumatriptan nasal spray in adolescent migraineurs: a randomized, double-blind, placebo-controlled, acute study. Headache. 2006 ; 46: 212-222
8. Linder SL, Mathew NT, Cady RK, Finlayson G, Ishkanian G, Lewis DW. Efficacy and tolerability of almotriptan in adolescents: a randomized, double-blind, placebo-controlled trial. Headache. 2008 ; 48: 1326-1336
9. Fernandes R, Ferreira JJ, Sampaio C. The placebo response in studies of acute migraine. J Pediatr. 2008 ; 152: 527-533
10. Evers S, Marziniak M, Frese A, Gralow I. Placebo efficacy in childhood and adolescence migraine: an analysis of double-blind and placebo-controlled studies. Cephalalgia. 2009 ; 29: 436-444
11. Winner P, Lewis D, Visser WH, Jiang K, Ahrens S, Evans JK. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: a randomized, double-blind, placebo-controlled study. Headache. 2002 ; 42: 49-55
12. Visser WH, Winner P, Strohmaier K, et al. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: results from a double-blind, single-attack study and two open-label, multiple-attack studies. Headache. 2004 ; 44: 891-899
13. Ahonen K, Hämäläinen ML, Eerola M, Hoppu K. A randomized trial of rizatriptan in migraine attacks in children. Neurology. 2006 ; 67: 1135-1140
14. Maunuksela EL, Olkkola KT, Korpela R. Measurement of pain in children with self-reporting and behavioral assessment. Clin Pharmacol Ther. 1987 ; 42: 137-141
15. Fraser IP, Han L, Han TH, et al. Pharmacokinetics and tolerability of rizatriptan in pediatric migraineurs in a randomized study. Headache. 2012 ; 52: 625-635
16. Swan SK, Alcorn H, Rodgers A, et al. Pharmacokinetic profile of rizatriptan 10-mg tablet and 10-mg orally disintegrating tablet administered with or without water in healthy subjects: an open-label, randomized, single-dose, 3-period crossover study. J Clin Pharmacol. 2006 ; 46: 172-178
17. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24: 9-160.
18. Tfelt-Hansen P, Block G, Dahlöf C, et al. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia. 2000 ; 20: 765-786
19. Ferrari MD, Loder E, McCarroll KA, Lines CR. Meta-analysis of rizatriptan efficacy in randomized controlled clinical trials. Cephalalgia. 2001 ; 21: 129-136
20. Lewis DW, Ashwal S, Dahl G, Dorbad D, Hirtz D, Prensky A, et al. Practice parameter: evaluation of children and adolescents with recurrent headaches: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2002 ; 59: 490-498